Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director | June 14, 2019 | June 19, 2019 |
| NATUS MEDICAL INCNTUS · Entity 125256 | Director · President and CEO | April 30, 2021 | May 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 14, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,386 |
Ending reported balance
After 2019-06-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-06-14 · Exercise / conversion · Acquired 2,458 · Balance 19,759 F1: Originally a 7,374 restricted stock unit award, 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2017 and 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2018. The vesting of the remaining 2,458 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Row 2 · 2019-06-14 · Exercise / conversion · Acquired 3,690 · Balance 23,449 F2: Originally a 7,380 restricted stock unit award, 3,690 restricted stock units became fully vested and non-forfeitable on December 4, 2018. The vesting of the remaining 3,690 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Row 3 · 2019-06-14 · Exercise / conversion · Acquired 3,937 · Balance 27,386 F3: Originally a 3,937 restricted stock unit award. The vesting of all 3,937 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. |
Filing footnotes · ownership attribution and instrument terms
F1: Originally a 7,374 restricted stock unit award, 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2017 and 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2018. The vesting of the remaining 2,458 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
F2: Originally a 7,380 restricted stock unit award, 3,690 restricted stock units became fully vested and non-forfeitable on December 4, 2018. The vesting of the remaining 3,690 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
F3: Originally a 3,937 restricted stock unit award. The vesting of all 3,937 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
NATUS MEDICAL INC
Report date April 30, 2021 · Filed May 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 191,810 |
Reported balance
After 2021-04-30 transaction · row 1
1 source rowRow 1 · 2021-04-30 · Grant · Acquired 489 · Balance 191,810 F1: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2020 through April 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on April 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2020 through April 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on April 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2021 Filed May 4, 2021 17:40 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 489 | $21.72 | $10,621.08 |
DisclosureSEC source: 0000878526-21-000028 · wf-form4_162016442674060.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,810 F1 · shares: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2020 through April 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on April 30, 2021. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:17 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | GrantNon-qualified Stock Option · Derivative | 66,716 | $0.00 Strike: $20.61 | $0.00 |
DisclosureSEC source: 0000878526-21-000008 · wf-form4_160988504366037.xml · derivative · entry 4 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,716 Underlying: Common Stock · 66,716 shares Expires 2031-01-04 F3 · derivative.exercise_date: Stock Options vest 25% on the anniversary of the grant over 4 years. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:17 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 66,716 | $20.61 | $1,375,016.76 |
DisclosureSEC source: 0000878526-21-000008 · wf-form4_160988504366037.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,321 F2 · shares: Restricted Stock Awards vest 25% on the anniversary of the grant over 4 years. Includes a total of 16,679 shares deferred pursuant to the terms of the deferred stock grant under Natus' Non-Qualified Deferred Compensation Plan. Read SEC document |
| January 04, 2021 Filed Apr 16, 2021 17:51 UTC Amendment | NATUS MEDICAL INC NTUS · Entity 125256 | GrantNon-qualified Stock Option · Derivative | 200,146 | $0.00 Strike: $20.61 | $0.00 |
DisclosureSEC source: 0000878526-21-000022 · wf-form4a_161860987877627.xml · derivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,146 Underlying: Common Stock · 200,146 shares Expires 2031-01-04 F1 · shares: This Form 4/A corrects an inadvertent error in the amount of stock options granted that was previously filed on January 5, 2021. F2 · derivative.exercise_date: Stock Options vest 25% on the anniversary of the grant over 4 years. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 17:17 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 14,985 | $20.04 | $300,299.40 |
DisclosureSEC source: 0000878526-21-000008 · wf-form4_160988504366037.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,605 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 17:17 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | OtherCommon Stock, $0.001 par value per share | 22,695 | $20.04 | $454,807.80 |
DisclosureSEC source: 0000878526-21-000008 · wf-form4_160988504366037.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,590 F1 · shares: Performance Restricted Stock cancelled previously reported on the August 2018 Form 4 due to performance goals not met. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:54 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 686 | $15.48 | $10,619.28 |
DisclosureSEC source: 0000878526-20-000094 · wf-form4_160444044965770.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,285 F1 · shares: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of May 1, 2020 through October 30, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on October 30, 2020. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:33 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 42,101 | $32.66 | $1,375,018.66 |
DisclosureSEC source: 0000878526-20-000012 · wf-form4_157904478981976.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,599 F1 · shares: Restricted Stock Award vest 25% on the anniversary of the grant over 4 years. Read SEC document |
| January 04, 2020 Filed Jan 6, 2020 20:04 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 2,980 | $32.59 | $97,118.20 |
DisclosureSEC source: 0000878526-20-000008 · wf-form4_157835903186689.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,498 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:04 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 19,279 | $32.66 | $629,652.14 |
DisclosureSEC source: 0000878526-20-000008 · wf-form4_157835903186689.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,478 Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 18:05 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 6,684 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0000878526-19-000136 · wf-form4_157593272510704.xml · derivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,240 Underlying: Common Stock · 6,684 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 18:05 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 6,684 | $31.54 | $210,813.36 |
DisclosureSEC source: 0000878526-19-000136 · wf-form4_157593272510704.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,757 F1 · price: 1.This transaction was executed in multiple trades a prices ranging from $31.45 to $31.60. The price reflected above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 18:05 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 7,600 | $22.50 | $171,000.00 |
DisclosureSEC source: 0000878526-19-000136 · wf-form4_157593272510704.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 4,268 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · derivative · entry 6 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324 Underlying: Common Stock · 4,268 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 4,268 | $34.32 | $146,477.76 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · nonDerivative · entry 4 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,841 F2 · price: 1.This transaction was executed in multiple trades a prices ranging from $34.30 to $34.33. The price reflected above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 5,000 | $22.50 | $112,500.00 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 4,408 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · derivative · entry 5 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592 Underlying: Common Stock · 4,408 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 4,408 | $33.65 | $148,329.20 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,109 F1 · price: 1.This transaction was executed in multiple trades a prices ranging from $33.59 to $33.85. The price reflected above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:58 UTC | NATUS MEDICAL INC NTUS · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 5,000 | $22.50 | $112,500.00 |
DisclosureSEC source: 0000878526-19-000134 · wf-form4_157307750074258.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2019 Filed Jun 19, 2019 16:53 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 3,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-000915 · form4.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Originally a 3,937 restricted stock unit award. The vesting of all 3,937 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Read SEC document |
| June 14, 2019 Filed Jun 19, 2019 16:53 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 3,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-000915 · form4.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Originally a 7,380 restricted stock unit award, 3,690 restricted stock units became fully vested and non-forfeitable on December 4, 2018. The vesting of the remaining 3,690 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Read SEC document |
| June 14, 2019 Filed Jun 19, 2019 16:53 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 2,458 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-000915 · form4.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Originally a 7,374 restricted stock unit award, 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2017 and 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2018. The vesting of the remaining 2,458 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 20:01 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 40,572 | $33.89 | $1,374,985.08 |
DisclosureSEC source: 0000878526-19-000022 · wf-form4_154837808791983.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · shares: Restricted Stock Award vest 25% on the anniversary of the grant over 4 years. Read SEC document |
| January 04, 2019 Filed Jan 4, 2019 17:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 2,980 | $33.38 | $99,472.40 |
DisclosureSEC source: 0000878526-19-000005 · wf-form4_154664193004460.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,945 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 8,625 | $32.92 | $283,935.00 |
DisclosureSEC source: 0000878526-19-000005 · wf-form4_154664193004460.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,925 Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 17:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 3,478 | $34.03 | $118,356.34 |
DisclosureSEC source: 0000878526-19-000005 · wf-form4_154664193004460.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,550 Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 17:23 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 4,348 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-18-001513 · form4.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 14, 2016, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 14, 2016, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 17:23 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 4,348 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-18-001513 · form4.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:37 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 3,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-18-001459 · form4.xml · derivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 18:01 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 3,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-18-001414 · form4.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,690 Underlying: Common Stock · 3,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 4, 2017, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 4, 2017, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 18:01 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 3,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-18-001414 · form4.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 16:28 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 4,072 | $36.54 | $148,790.88 |
DisclosureSEC source: 0000878526-18-000144 · wf-form4_153574728571235.xml · nonDerivative · entry 4 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,028 F3 · price: This transaction was executed in multiple trades at prices ranging from $36.50 to $36.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 16:28 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 31,345 | $13.24 Strike: $13.24 | $415,007.80 |
DisclosureSEC source: 0000878526-18-000144 · wf-form4_153574728571235.xml · derivative · entry 5 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,345 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 16:28 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 12,183 | $36.96 | $450,283.68 |
DisclosureSEC source: 0000878526-18-000144 · wf-form4_153574728571235.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,100 F2 · price: This transaction was executed in multiple trades at prices ranging from $36.85 to $37.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 16:28 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 31,345 | $36.85 | $1,155,063.25 |
DisclosureSEC source: 0000878526-18-000144 · wf-form4_153574728571235.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,283 F1 · price: This transaction was executed in multiple trades at prices ranging from $36.75 to $37.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 16:28 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 31,345 | $13.24 | $415,007.80 |
DisclosureSEC source: 0000878526-18-000144 · wf-form4_153574728571235.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 29, 2018 13:46 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantNon-qualified Stock Option · Derivative | 74,124 | $0.00 Strike: $35.25 | $0.00 |
DisclosureSEC source: 0000878526-18-000142 · wf-form4_153556479020914.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,124 Underlying: Common Stock · 74,124 shares Expires 2024-07-11 F2 · derivative.exercise_date: Stock Options vest over 4 years from the date of the grant. 25% will vest on the first anniversary of the grant, 25% on the second anniversary of the grant, 25% on the third anniversary of the grant, and 25% on the fourth anniversary of the grant. Read SEC document |
| August 24, 2018 Filed Aug 29, 2018 13:46 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 22,695 | $35.25 | $799,998.75 |
DisclosureSEC source: 0000878526-18-000142 · wf-form4_153556479020914.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,283 F1 · shares: Performance Restricted Stock will be eligible to vest after 2.5 years and based upon performance goals set forth. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 17:57 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 2,458 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-18-000758 · form4.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 Underlying: Common Stock · 2,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 27, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on June 27, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On June 27, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on June 27, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 17:57 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 2,458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-18-000758 · form4.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 19:20 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 34,100 | $38.20 | $1,302,620.00 |
DisclosureSEC source: 0000878526-18-000006 · wf-form4_151502520747617.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,588 F1 · shares: Restricted Stock Award vest over 4 years from the date of the grant. 50% will vest on the second anniversary of the grant, 25% on the third anniversary of the grant, and 25% on the fourth anniversary of the grant. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 19:20 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 11,927 | $38.20 | $455,611.40 |
DisclosureSEC source: 0000878526-18-000006 · wf-form4_151502520747617.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,488 Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 18:08 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 4,347 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-17-001306 · form4.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,348 Underlying: Common Stock · 4,347 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 14, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 14, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 18:08 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 4,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-17-001306 · form4.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 19:47 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 7,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-045234 · doc1.xml · derivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,380 Underlying: Common Stock · 7,380 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 19:04 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 2,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-026707 · doc1.xml · derivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,916 Underlying: Common Stock · 2,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 27, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on June 27, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On June 27, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on June 27, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 19:04 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 2,458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-026707 · doc1.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 18:32 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 8,137 | $38.55 | $313,681.35 |
DisclosureSEC source: 0000878526-17-000030 · wf-form4_149203636024912.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,415 Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 20:08 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock, $0.001 par value per share | 32,000 | $34.80 | $1,113,600.00 |
DisclosureSEC source: 0000878526-17-000008 · wf-form4_148366490739066.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,552 F1 · shares: Restricted Stock Award vest over 4 years from the date of the grant. 50% will vest on the second anniversary of the grant, 25% on the third anniversary of the grant, and 25% on the fourth anniversary of the grant. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 20:08 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 9,428 | $34.80 | $328,094.40 |
DisclosureSEC source: 0000878526-17-000008 · wf-form4_148366490739066.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,552 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.